Investigational peptide

BPC-157

BPC-157 is a 15-amino-acid peptide in no FDA-approved drug.1 FDA gives its half-life as 5.3 minutes in dogs and 15.2 in rats after one intravenous dose and found no human pharmacokinetic data for oral or subcutaneous doses.1

Moderate evidenceGet the app

Level after one dose

BPC-157 after one dose: 50% at ~30 min, 25% at 60 min, 12.5% at 90 min.

Drawn from the half-life in the app's model, ~30 min. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

6%The 10th most tracked compound in Milligram: of people who track compounds in Milligram logged BPC-157 in the last 90 days.

Schedule

  1. Daily75%
  2. Every other day18%
  3. Twice a week5%
  4. Weekly2%
  5. Less often0%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 250 and 500 mcg per dose; the median was 500 mcg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging BPC-157 who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

2

Overview

The app lists BPC-157 as a healing peptide with a half-life of about 30 minutes, 95% bioavailability, a typical dose of 250–500 mcg/day, subcutaneous and oral routes and a Moderate Evidence grade. The figures and the grade are the app's own.

FDA's briefing document says BPC-157 "is also known as Bepecin or PL-14736, which is a peptide that is reported to be comprised of 15 amino acids".1 FDA states that BPC-157 (free base) was first synthesized in the early 1990s by researchers at a university in Croatia, and that "BPC-157 is a common name and not a United States Adopted Name".1

FDA's briefing document states that "the molecular targets for BPC-157 have not been identified and its mechanisms of action remain poorly understood".1 FDA's nonclinical summary adds that dose-response relationships for BPC-157 to suppress GI and hepatic injuries have not been established.1

McGuire and colleagues (University of Utah, Current Reviews in Musculoskeletal Medicine, 2025) write that BPC-157 "has demonstrated regenerative properties across numerous animal models" and "activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis", and that "human data are extremely limited".4 FDA, by contrast, states that the molecular targets have not been identified.1

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~30 min
Bioavailability
95%
Typical dose
250–500 mcg/day
Route
SubQ, oral
Time to peak
~30 min

The table sets the app's figures beside what the sources report; the measured values come from rats and beagle dogs.

Table 4.1Half-life and pharmacokinetics4 rows
FigureThe app's figureWhat the sources report
Half-life~30 minHe and colleagues (Air Force Medical University, Xi'an; Frontiers in Pharmacology, 2022) report an elimination half-life of less than 30 minutes after intravenous and intramuscular doses in rats and beagle dogs.5 FDA's account of a single intravenous dose gives 5.3 minutes in dogs (6 μg/kg) and 15.2 minutes in rats (20 μg/kg).1 FDA writes that there is no information to assess the pharmacokinetics of BPC-157 in humans, and that "it does not appear that BPC-157 is absorbed systemically when given as a rectal enema".1
Bioavailability95%After intramuscular injection, a mean absolute bioavailability of approximately 14% to 19% in rats and 45% to 51% in beagle dogs.5 The sources cited report no subcutaneous or oral bioavailability figure, and FDA found no human pharmacokinetic data after oral or subcutaneous doses.1
Time to peak~30 minNo time to peak is reported in the sources cited.1
RouteSubQ, oralHuman studies gave BPC-157 as an enema, an intra-articular or intravesical injection, or an intravenous infusion; an oral tablet study (NCT02637284) is registered.1,6

He and colleagues declare no commercial or financial relationships and write that they had "previously established a solid-phase synthesis process for BPC157".5

Mateescu and colleagues (Pharmaceutics, 2026) write of "a plasma half-life of under 30 min-confirmed preclinically and in a preliminary two-subject human pilot-contrasts with prolonged biological effects lasting hours to days".7 The PubMed record of the two-person intravenous pilot by Lee and Burgess reports results for blood biomarkers and no half-life.12

The chart is an illustration of the app's own figures; none of the sources cited reports a human concentration curve.

Level over 3 days

Interval between doses

Level, as a share of the peak after one 250 mcg dose

As studied: every day15. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 0.5 hours. It is not a measured level or a suggested dose.

5

Human studies

FDA's briefing document counts five clinical studies that used BPC-157, and the systematic review by Poolton and colleagues included three studies with 30 people in total.1,2 Tham and colleagues (Journal of the American Academy of Orthopaedic Surgeons, 2026) write that human musculoskeletal evidence for BPC-157 "is limited to one small retrospective uncontrolled case series without validated outcome measures".8 A query of PubMed on 16 November 2026 for BPC-157, BPC157 or "BPC 157" in the title or summary text returned 231 records, of which 52 are tagged as Review and 1 as Systematic Review, 1 as a case report and none as a clinical trial or randomised controlled trial. The case-report record describes three patients with nerve injury after dental procedures who received several agents together, among them BPC-157, and the authors write that "it is impossible to determine whether the observed clinical course resulted from one agent, a combination of agents, associations among interventions, or the expected natural history of recovery".9 The paper declares no commercial or financial relationships, and its last author, James LaValle, lists the American Academy of Anti-Aging Medicine as an affiliation.9

Table 5.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Veljaca and colleagues, meeting reports 2002 and 20031Placebo-controlled phase 1 tolerability and pharmacokinetic study of BPC-157 enema, as summarised by FDA1Healthy male volunteers: 32 randomised, 24 received BPC-15710.25, 0.5, 1 and 2 mg/kg or placebo enema; one dose, a one-week washout, then seven daily doses1The authors report no significant adverse events attributable to treatment; headache and flatulence "occurred with no obvious difference in frequency or severity" against placebo.1 FDA writes that the authors of the two enema studies that measured plasma levels report that BPC-157 was not detected in plasma samples, and that in the 2003 meeting report "most" plasma concentrations were below the lower limit of quantification, with no further details provided.1
Ruenzi and colleagues, meeting report 20051Multicentre, randomised, double-blind, placebo-controlled enema study in mild to moderate ulcerative colitis153 randomised 1:1; 46 completed1BPC-157 (PL 14736) enema 80 mg or placebo once daily for two weeks1Change in a disease activity index that FDA notes was not clearly defined in the meeting report: -3.2 points (95% CI -5.58, -0.82) with BPC-157 and -1.6 (95% CI -3.86, 0.67) with placebo, an estimated difference of 1.6 points (95% CI -4.84, 1.62, an interval that includes zero); 3 withdrawn for an adverse event with BPC-157 and 2 with placebo, "mainly progression of UC". The authors write "There was no difference in the frequency or type of adverse events in comparison with placebo".1
Lee and Padgett, Alternative Therapies in Health and Medicine, 202110Retrospective chart review with a phone survey, Institute for Hormonal Balance, Orlando, Florida1017 patients; 16 reached by phone: 12 given BPC 157 alone, 4 given BPC 157 with thymosin-beta-410Intra-articular knee injection; BPC-157 2 to 4 mg in 1 to 2 doses according to FDA1,10BPC 157 alone: 11 of 12 (91.6%) significant improvement in knee pain, 1 of 12 no improvement. With thymosin-beta-4: 75% significant improvement, 25% no relief.10
Lee, Walker and Ayadi, Alternative Therapies in Health and Medicine, 202411Pilot study at a private clinic in moderate to severe interstitial cystitis, called a single-arm study by FDA and a retrospective pilot study by Poolton and colleagues; Global Response Assessment questionnaire11,1,212 women with moderate to severe interstitial cystitis, aged 39 to 76 (mean 58.3); none had responded to pentosan polysulfate1110 mg in total injected around the area of inflammation of the bladder during a single procedure11Complete resolution of symptoms after one treatment in 10 of 12 patients, who rated their success at 100%; the other 2 of 12 rated it at 80%. No one dropped out and no adverse events were reported.11
Lee and Burgess, Alternative Therapies in Health and Medicine, 202512Single-arm intravenous safety pilot at a private clinic in Florida122 adults, a 58-year-old male and a 68-year-old female, each of whom had received intravenous BPC-157 before the trial1210 mg on day 1 and 20 mg on day 2, each in 250 cc of normal saline over one hour12No measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid or blood glucose levels; the infusion was tolerated, with no side effects reported.12

Deeper analysis: the ulcerative colitis enema study, 2005

Ruenzi and colleagues (the UCS Group) reported the study in Gastroenterology in 2005, and FDA summarises it from the meeting report.1 FDA writes that "several details of the trial are lacking" and that the data "are therefore inadequate to support the efficacy and safety of BPC-157 given as an enema for two weeks for the treatment of UC".1 FDA's account does not name a funder; the title of a 2006 review by Sikirić and colleagues (Department of Pharmacology, University of Zagreb) places PL 14736 under "Pliva, Croatia".13

Deeper analysis: the 2021 knee chart review

In the 2021 knee chart review, follow-up varied because the study was retrospective, patients rated their own pain, and the authors state that "No specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living".10 FDA notes that the BPC-157 was compounded by Tailor Made Compounding in Nicholasville, Kentucky, and the PubMed record carries no funding or conflict-of-interest statement.1,10

Deeper analysis: the 2024 and 2025 pilots by Lee and colleagues

The PubMed records for the 2024 and 2025 pilots carry no funding or conflict-of-interest statement, and FDA notes that the BPC-157 in both was compounded by a 503A pharmacy in the United States that did not wish to disclose its name.11,12,1

Deeper analysis: a 2026 rat Achilles tendon study, BPC-157 arm

Biçer and colleagues (Bağcılar Training and Research Hospital, Istanbul; Joint Diseases and Related Surgery, 2026) randomised 32 male Sprague-Dawley rats after Achilles tendon transection and repair into four groups of 8: control, BPC-157 at 10 µg/kg/day intraperitoneally for 30 postoperative days, TB-500, and both peptides, with "n = 4 per group" for all nonbiomechanical analyses.14 Median maximum load to failure was 26.91 N in controls and 37.16 N with BPC-157, which "did not differ significantly from controls (adjusted p = 0.389)"; the only significant pairwise difference was the TB-500 group against controls (adjusted p = 0.0406).14 The BPC-157 group did not differ significantly from controls on the total Bonar score (p = 0.273), total Movin score (p = 0.601) or immunohistochemical type I collagen expression (p = 0.242), while Sirius red type I collagen intensity was higher (p = 0.009).14 The authors list as limitations a single time point, healthy young male rats, no functional assessment, no molecular analyses, no a priori power calculation and no blinding during surgery or treatment; they declared no conflicts of interest or financial support, and the BPC-157 came from Peptide Sciences (Boca Raton, Florida).14

Registered studies

A ClinicalTrials.gov query on 16 November 2026 for BPC-157, BPC157 or Bepecin returned four registered studies. NCT07437547 (sponsor Hudson Biotech) is a randomised, double-blind, placebo-controlled phase 2 trial in acute grade II hamstring strain, with 120 participants estimated, subcutaneous injection once daily for 14 days, recruiting.15 NCT07803250 (University of Arkansas) is a randomised pilot in arthroscopic rotator cuff repair with a sham comparator, subcutaneous injection once daily for 90 days and an estimated start on 1 January 2027; the record describes saline injections and also a "Sham (No Treatment)" intervention, and gives 20 patients in its summary and 30 as estimated enrollment.16 NCT02637284 (PharmaCotherapia d.o.o.) is a randomised, placebo-controlled phase 1 pilot of oral tablets containing 1 mg of BPC-157, with estimated enrollment of 42 healthy volunteers, a status of unknown and a last update in December 2015; FDA notes no results are posted and that it found no associated published study.6,1 NCT07752381 (Parlay Wellness) is a completed single-group study of 40 participants who consumed two gummies daily containing BPC-157.17

6

Doses reported in studies

The app lists a typical dose of 250–500 mcg/day. FDA writes that "There is no approved product containing BPC-157-related BDSs in any country at this time", so the sources cited contain no label dose.1 FDA lists the products proposed in the two withdrawn nominations as including capsules of 250 μg, 500 μg and 1 mg and an injection of 2,000 μg/mL.1

Table 6.1Doses reported in studies7 rows
SourceSubstance and routeDoseFrequency and length
Veljaca and colleagues, 2002 and 20031BPC-157 enema, healthy subjects10.25, 0.5, 1 and 2 mg/kg1A single dose, a one-week washout, then seven daily doses1
Ruenzi and colleagues, 20051BPC-157 enema, ulcerative colitis180 mg1Once daily for two weeks1
Lee and Padgett, 20211,10BPC-157, intra-articular, knee12 to 4 mg11 to 2 doses1
Lee and colleagues, 202411BPC-157, intravesical injection11 mg at each of 10 sites, 10 mg in total1A single procedure1
Lee and Burgess, 202512BPC-157, intravenous infusion1210 mg, then 20 mg12Day 1 and day 2, each over one hour12
NCT02637284, registered 20156Oral tablets containing 1 mg of BPC-157, healthy volunteers61, 3 or 6 tablets once; then 3 tablets6Phase 1b: three times daily for 2 weeks6
NCT07752381, registered 202617Peptide gummies containing BPC-157, 40 participants17500 µg per serving; the record does not state how many gummies make a serving17Two gummies daily for 8 weeks17

No published human study in the table reports a dose of 250 to 500 mcg; the record NCT07752381 lists 500 µg per serving.17

Reports in people

FDA states that "No serious adverse events appear to have been reported" in the five clinical studies, and adds that they "were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data".1 Poolton and colleagues found no treatment-related adverse events in their three human studies and rated those studies poor in quality.2

FDA's adverse event database returned three reports for BPC-157 through 4 December 2025.1 They were 9 days of redness and swelling around the injection site in a 55-year-old woman who was also using injectable compounded thymosin, shortness of breath that led to an emergency room visit in a 28-year-old male using BPC-157 acetate, and "diffuse hyperpigmentation and gingival darkening" in a 40-year-old woman using a product containing BPC-157 and TB500, which returned on rechallenge; she stopped all peptides and had no further reactions, and FDA writes that "The AEs were likely due to the drug product considering that the AEs occurred upon rechallenge".1 FDA writes that "because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs", and that it "cannot make definitive conclusions regarding the safety of BPC-157 based on FAERS data alone".1

Animal safety studies

Xu and colleagues (Fourth Military Medical University, Xi'an; Regulatory Toxicology and Pharmacology, 2020) report that BPC157 "was well tolerated and did not cause any serious toxicity in mice, rats, rabbits and dogs", with a decrease in creatinine level at 2 mg/kg in dogs after which "the animals recovered spontaneously after 2 weeks of withdrawal", and write that the data "contribute to the initiation of an ongoing clinical study" and declare no competing interests.18 FDA reads the 28-day intramuscular studies in rats and dogs as "associated with clinically relevant safety signals", namely "aPTT shortening and aPTT prolongation (suggestive of altered clotting properties) in rats and dogs, respectively" and "liver-associated signals (increased serum ALT, glucose, and TG levels)".1 FDA writes that the assays of Xu and colleagues in bacteria, CHL cells and mouse bone marrow "demonstrate that BPC-157 is not a mutagen", that rats given up to 4.0 mg/kg intramuscularly in pregnancy showed no effect on the incidence of fetal malformations, that the article describes no complete reproductive-cycle study, and that it "did not identify carcinogenicity studies of BPC-157 (free base) or BPC-157 acetate".1

Product quality and immunogenicity

FDA writes that, as a peptide with 15 amino acids given by a parenteral or nasal route, BPC-157 "may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities", that "inherent immunogenic risk for BPC-157 administered orally is likely to be low", and that it did not identify any studies that formally investigated the immunogenicity of BPC-157 products.1 Tham and colleagues, reviewing BPC-157, thymosin beta-4 and products marketed as TB-500, write that commercial products "raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency".8

8

Bloodwork and markers

Sources in this part

  1. 12Lee et al., 2025

The app lists no markers for BPC-157. In the 2025 intravenous pilot the infusions "resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels" in 2 adults.12

FDA's July 2026 briefing document evaluated BPC-157 for the 503A Bulks List and gives four reasons for proposing against it: the substances are not well characterized from a physiochemical perspective, information on safety and immunogenicity is lacking, evidence of effectiveness in ulcerative colitis is insufficient, and approved drugs exist for ulcerative colitis.1

Table 9.1Regulatory and anti-doping status3 rows
RegulatorStatus as stated in the source
FDA, July 2026 briefing document1Proposal not to add BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List1
Australia, TGA final decision of 22 May 202419Schedule 4 entry for BPC-157 and Appendix D, clause 5 ("Poisons for which possession without authority is illegal"); implementation date 1 June 202419,20
WADA 2026 Prohibited List21Named in S0 non-approved substances, prohibited at all times (in and out of competition); all S0 substances are Specified Substances21

AJMC reports that on 23 July the advisory committee "voted 8-6, with 1 abstention, to recommend BPC-157, KPV, and TB-500", overriding "career scientists who had recommended against including any of the 7", while RAPS writes that the committee "was nearly evenly divided" on BPC-157 and that FDA staff "recommended against adding these peptides to the 503A Bulks List due to safety and efficacy concerns".23,22 AJMC writes that "None of the peptides have been added to the 503A Bulks List, and none is an FDA-approved drug" and that FDA "must still decide whether to accept the committee's nonbinding recommendations"; the sources cited do not cover any FDA action after AJMC's report of 31 July 2026.23 RAPS notes that, before the meeting, eight new members were added, "many of whom have alleged ties to prescribing or promoting peptides".22

The TGA's delegate proposed the Schedule 4 and Appendix D entries in response to 48 referrals for importation of BPC-157 received since 1 July 2022, to align BPC-157 with other performance- and image-enhancing substances.19 The 2024 interim notice lists "High risk of misuse and abuse within athletes, fitness, wellness and anti-ageing consumer markets" and "Short-term and long-term safety of BPC-157 intake is unknown", and the delegate wrote of "only a small number of peer-reviewed studies that largely originate from a single laboratory" supporting the therapeutic claims.20 The sources cited here do not cover later amendments to the Poisons Standard.

Tham and colleagues state that "Validated dosing, pharmacokinetic, and long-term safety data are lacking" for BPC-157.8 FDA writes that "There is insufficient clinical safety information to characterize the safety profile of BPC-157 (free base) and BPC-157 acetate", and that it found no studies giving BPC-157 to people by the oral, subcutaneous, nasal or transdermal route.1

Sikirić and colleagues (University of Zagreb, authors of the 1993 paper that describes the BPC peptide) replied to a 2025 review by Józwiak and colleagues that they describe as speculating about "angiogenesis toward tumorogenesis" and neurodegenerative diseases, wrote that BPC 157 "presents prominent anti-tumor potential, in vivo and in vitro", name mice and rats for their neurodegenerative disease models, and declare no conflict of interest.24,3

What is the half-life of BPC-157?

The app lists a half-life of about 30 minutes for BPC-157. FDA writes that there is no information to assess the pharmacokinetics of BPC-157 in humans, and the PubMed record of the two-person intravenous pilot by Lee and Burgess lists no half-life; Mateescu and colleagues refer to a preliminary two-subject human pilot.1,12,7 In rats and beagle dogs the elimination half-life was less than 30 minutes, and FDA reports 5.3 minutes in dogs and 15.2 minutes in rats after one intravenous dose.5,1

What is BPC-157?

FDA's briefing document describes BPC-157 as a peptide "reported to be comprised of 15 amino acids", also known as Bepecin or PL-14736.1

Is BPC-157 FDA approved?

No: FDA states that BPC-157 (free base) and its acetate form are not a component of an FDA-approved drug.1 FDA's briefing document proposes not adding either to the 503A Bulks List, and AJMC reported on 31 July 2026 that an advisory committee voted 8-6, with 1 abstention, to recommend BPC-157, KPV and TB-500, a nonbinding recommendation.1,23

Is BPC-157 banned by WADA?

Yes, for athletes bound by the World Anti-Doping Code: the WADA 2026 Prohibited List, an International Standard under that Code, names BPC-157 in section S0, non-approved substances, prohibited at all times, in and out of competition.21

Is BPC-157 legal in Australia?

The TGA's final decision of 22 May 2024 entered BPC-157 in Schedule 4 and in Appendix D, clause 5, "Poisons for which possession without authority is illegal", with an implementation date of 1 June 2024.19,20

Has BPC-157 been studied in humans?

FDA counts five clinical studies: an enema study in 24 healthy subjects, an enema study in ulcerative colitis, a knee injection review, an intravesical pilot and an intravenous pilot in 2 adults.1 Poolton and colleagues rated the overall certainty of evidence in people as very low.2

Has oral BPC-157 been studied in people?

FDA found no studies that gave BPC-157 to people by the oral route and no human pharmacokinetic data after oral doses.1 Registered oral studies are NCT02637284 (tablets) and the completed NCT07752381 (gummies; 40 participants; 500 µg per serving in the record).6,17

What side effects have been reported for BPC-157?

FDA's adverse event database returned three reports: an injection-site reaction in a woman also using injectable thymosin, shortness of breath in a man, and diffuse hyperpigmentation and gingival darkening in a woman using a BPC-157 and TB500 product.1

13

References

  1. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23 - 24, 2026: BPC-157 – Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). 2026. FDA briefing document
  2. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. PMID 42885452
  3. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 1993. PMID 8298609
  4. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PMID 40789979
  5. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. PMID 36588717
  6. PharmaCotherapia d.o.o. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source. ClinicalTrials.gov NCT02637284, 2015. NCT02637284
  7. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics 2026. PMID 42198317
  8. Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg 2026. PMID 42937313
  9. Froum S, Estrin N, Pico G, et al. Case Report: Regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health 2026. PMC13661421
  10. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PMID 34324435
  11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PMID 39325560
  12. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PMID 40131143
  13. Sikirić P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006. PMID 17186181
  14. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg 2026. Joint Dis Relat Surg, full text
  15. Hudson Biotech. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. ClinicalTrials.gov NCT07437547, 2026. NCT07437547
  16. University of Arkansas. Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery. ClinicalTrials.gov NCT07803250, 2026. NCT07803250
  17. Parlay Wellness. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. ClinicalTrials.gov NCT07752381, 2026. NCT07752381
  18. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol 2020. PMID 32334036
  19. Therapeutic Goods Administration. Notice of final decisions to amend (or not amend) the current Poisons Standard (November 2023 meetings; published 22 May 2024). 2024. TGA final decision notice
  20. Therapeutic Goods Administration. Notice of interim decisions to amend (or not amend) the current Poisons Standard (November 2023 meetings; published 3 April 2024). 2024. TGA interim decision notice
  21. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. 2026. WADA 2026 list
  22. Eglovitch JS. FDA advisory committee backs two controversial peptides. Regulatory Affairs Professionals Society, 23 July 2026. RAPS report
  23. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC, 31 July 2026. AJMC report
  24. Sikirić P, Seiwerth S, Skrtic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Pharmaceuticals (Basel) 2025. PMID 41155565